Company research
AC Immune SA
CIK 1651625Updated Nov 6, 2026
ACIU price & chart
Loading TradingView…
NASDAQ:ACIU on TradingView ↗About the company
AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases. Building on more than two decades of expertise in the field of misfolded proteins, AC Immune is advancing a diversified portfolio of disease-modifying active immunotherapies and small molecule approaches. AC Immune’s wholly-owned pipeline includes its lead program, ACI-7104, in Phase 2 development for early Parkinson's disease (PD), a progressive neurodegenerative disease affecting c.10 million people worldwide with no approved disease-modifying therapies today. By targeting misfolded alpha-synuclein, a key driver of PD progression, ACI-7104 aims to slow, or halt, the spread of the disease throughout the brain before irreversible neurological damage occurs. The Company is also advancing ACI-19764, an NLRP3 inflammasome inhibitor in Phase 1, and a preclinical intracellular small molecule alpha-synuclein program.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CHFSource
Source
Source
cash flow · annual statements
| Line item | Q4 2022 | Q4 2021 | Q3 2022 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossCHF | — | — | -13,516,000Source | -15,918,000Source | -21,189,000Source | -22,760,000Source | -16,833,000Source | -19,643,000Source | -70,447,000Source | -50,916,000Source | -54,233,000Source | -70,753,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCHF | — | — | — | — | — | — | — | — | — | 14,800,000Source | -14,800,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableCHF | — | — | — | — | — | — | — | — | -592,000Source | 977,000Source | 770,000Source | -1,073,000Source |
| AdjustmentsForSharebasedPaymentsCHF | — | — | — | — | — | — | — | — | 4,396,000Source | 5,470,000Source | 4,365,000Source | 3,330,000Source |
| GeneralAndAdministrativeExpenseCHF | — | — | 3,274,000Source | 5,420,000Source | 3,896,000Source | 4,551,000Source | 3,681,000Source | 4,374,000Source | 16,094,000Source | 17,259,000Source | 15,305,000Source | 15,789,000Source |
| InterestPaidClassifiedAsOperatingActivitiesCHF | — | — | — | — | — | — | — | — | 174,000Source | 113,000Source | 163,000Source | 470,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesCHF | — | — | — | — | — | — | — | — | 1,897,000Source | 1,563,000Source | 595,000Source | 69,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCHF | — | — | — | — | — | — | — | — | 1,026,000Source | 683,000Source | 548,000Source | 569,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesCHF | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCHF | — | — | — | — | — | — | — | — | 15,000Source | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2022 | Q4 2021 | Q3 2022 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueCHF | — | — | 3,934,000Source | — | 1,306,000Source | 687,000Source | — | — | 3,573,000Source | 27,309,000Source | 14,801,000Source | 3,935,000Source |
| Additional Financial Items | ||||||||||||
| BasicEarningsLossPerShareCHF/shares | — | — | -0.16Source | -0.22Source | -0.21Source | -0.23Source | -0.2Source | -0.23Source | -0.7Source | -0.51Source | -0.64Source | -0.85Source |
| DepreciationRightofuseAssetsCHF | — | — | 142,000Source | 141,000Source | 260,000Source | 169,000Source | 134,000Source | 141,000Source | 1,110,000Source | 677,000Source | 543,000Source | 566,000Source |
| DilutedEarningsLossPerShareCHF/shares | — | — | -0.16Source | -0.22Source | -0.21Source | -0.23Source | -0.2Source | -0.23Source | -0.7Source | -0.51Source | -0.64Source | -0.85Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCHF | — | — | — | — | 1,100,000Source | 1,400,000Source | — | — | — | 5,500,000Source | 4,400,000Source | 3,300,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedCHF | — | — | 212,000Source | 231,000Source | 188,000Source | 170,000Source | 189,000Source | 173,000Source | 690,000Source | 752,000Source | 793,000Source | 750,000Source |
| FinanceCostsCHF | — | — | 77,000Source | 181,000Source | 50,000Source | 34,000Source | 27,000Source | 126,000Source | 191,000Source | 133,000Source | 176,000Source | 355,000Source |
| FinanceIncomeCHF | — | — | 11,000Source | 4,424,000Source | 458,000Source | 739,000Source | 259,000Source | — | 1,865,000Source | 3,196,000Source | 1,044,000Source | 69,000Source |
| GeneralAndAdministrativeExpenseCHF | — | — | 3,274,000Source | 5,420,000Source | 3,896,000Source | 4,551,000Source | 3,681,000Source | 4,374,000Source | 16,094,000Source | 17,259,000Source | 15,305,000Source | 15,789,000Source |
| IncomeTaxExpenseContinuingOperationsCHF | — | — | 4,000Source | — | — | — | 3,000Source | 3,000Source | 0Source | 3,000Source | 10,000Source | 13,000Source |
| InterestExpenseOnLeaseLiabilitiesCHF | — | — | 17,000Source | 17,000Source | 45,000Source | 29,000Source | 24,000Source | 18,000Source | 174,000Source | 113,000Source | 90,000Source | 68,000Source |
| OtherOperatingIncomeExpenseCHF | — | — | 262,000Source | 255,000Source | 28,000Source | 41,000Source | 317,000Source | 207,000Source | 94,000Source | 142,000Source | 1,486,000Source | 1,343,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansCHF | — | — | — | — | — | — | — | — | 301,000Source | 1,794,000Source | 2,455,000Source | 1,751,000Source |
| ProfitLossBeforeTaxCHF | — | — | -13,512,000Source | -15,918,000Source | -21,189,000Source | -22,760,000Source | -16,830,000Source | -19,640,000Source | -70,447,000Source | -50,913,000Source | -54,223,000Source | -70,740,000Source |
| ProfitLossFromOperatingActivitiesCHF | — | — | -13,463,000Source | -20,283,000Source | -19,388,000Source | -20,961,000Source | -17,046,000Source | -19,859,000Source | -69,318,000Source | -52,378,000Source | -53,624,000Source | -70,847,000Source |
| ResearchAndDevelopmentExpenseCHF | — | — | 14,385,000Source | 15,118,000Source | 16,826,000Source | 17,138,000Source | 13,682,000Source | 15,692,000Source | 56,436,000Source | 62,570,000Source | 54,606,000Source | 60,336,000Source |
Filing attachments
aciu-ex99d1.htm · 6-K · 2026-11-04
Exhibit 99.1 PRESS RELEASE AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead cand…
Read attachment ↗aciu-20260923xex99d1.htm · 6-K · 2026-09-23
Exhibit 99.1 PRESS RELEASE AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 ●All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated ●Strong immunogenicity demonstrated, with 100% response rate after three immunizations ●Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement ●Discussions with FDA regarding future development path planned for …
Read attachment ↗aciu-20260820xex99d1.htm · 6-K · 2026-08-20
Exhibit 99.1 PRESS RELEASE AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ●ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome ●Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration ●Based on PK data the therapeutic dose is expected to be ≤10mg once daily ●To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a…
Read attachment ↗aciu-20260811xex99d1.htm · 6-K · 2026-08-11
Exhibit 99.1 PRESS RELEASE AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) ●Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance ●Recent positive interim results showed safety and immunogenicity with early signals of activity ●Full week-100 results from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, August 11, 2026 - AC Immune SA …
Read attachment ↗aciu-20260630xex99d1.htm · 6-K · 2026-08-05
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2026 2025 Assets Non-current assets Property, plant and equipment 5 1,919 1,989 Right-of-use assets …
Read attachment ↗aciu-20260630xex99d2.htm · 6-K · 2026-08-05
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the six months ended June 30, 2026, included as Exhibit 99.1 to this Report on Form 6-K. We also recommend that y…
Read attachment ↗